Dr. Srinivasan heads Viking’s Discovery and Preclinical Sciences group and brings over 25 years of pharmaceutical and biotechnology industry experience. He has advanced numerous therapies to IND and contributed to several late-stage or marketed products, including Augtyro™ (NSCLC), Rebyota® (C. difficile infection/GI), Apraglutide (SBS/GI), Firmagon® (prostate cancer), OCE-205 (ESLD/hepatology), NVI-100 (migraine/CNS), and Korsura™ (CKD-pruritus). Prior to joining Viking, he served as Senior Vice President at Atomwise Inc. (now Numerion Labs) and as Vice President at Turning Point Therapeutics (acquired by Bristol Myers Squibb) and Ferring Pharmaceuticals, leading teams in discovery and early clinical development. Earlier in his career, he held scientific leadership roles at Pfizer and Hoffmann-La Roche Inc. Dr. Srinivasan also serves as a research advisor and consultant at the Broad Institute’s Center for the Development of Therapeutics. He holds a Ph.D. in pharmaceutical sciences from the University of Georgia and a bachelor’s degree in pharmacy (honors) from the Birla Institute of Technology and Science (BITS), India.